PRESS RELEASE | Basel, Switzerland, March 10, 2022
Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress
- Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th March 2022 in Basel, Switzerland, where Chief Executive Officer Klaas Zuideveld will be presenting data on the Company’s mRNA engineering technology and its lead therapeutic candidate, VMB-100.
Versameb has developed a groundbreaking, proprietary technology platform which optimizes the application of functional RNA in different disease contexts. Its lead therapeutic candidate VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.
RNA Leaders World Congress
Date: 16-17 March 2022, Congress Center, Basel, Switzerland
Presentation by: Klaas Zuideveld, Chief Executive Officer, Versameb
Title: Regeneration of urethral muscle in Stress Urinary Incontinence using engineered mRNA
Date & Time: Wednesday, 16th March 2022, 12.00pm CET
Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting data on our proprietary platform and lead asset at the RNA Leaders World Congress on the 16th of March 2022. Our next generation RNA platform has demonstrated pioneering potential for mRNA-based therapeutics in Stress Urinary Incontinence and other indications. We are committed and working towards bringing our innovative technology to patients suffering from SUI, an unmet medical need with no drug treatment approved for restoration.”
Our understanding of RNA biology continues to mature. With that in mind, the first annual RNA Leaders World Congress brings together more than 150 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders World Congress. Topics include the latest advances in RNA biology, updates from the companies developing new therapies and services partners who are helping to deliver drugs to patients. Versameb are bronze sponsors of the Congress.
If you would like to meet with the Versameb team at the above event, please contact us at the details provided below. For more information, please visit us at www.versameb.com/upcoming-conferences-events.
Contact for media enquiries:
Dr Klaas Zuideveld, CEO
Optimum Strategic Communications
Mary Clark, Supriya Mathur, Zoe Bolt
Tel: +44 (0)20 3882 9621